January 2026 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” In this case report, a 62-year-old woman with suspected discoid lupus erythematosus experienced worsening skin and hair symptoms despite treatment with topical corticosteroids, immunomodulatory therapy, and hydroxychloroquine, leading to her referral to a tertiary dermatology center.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.
3 citations
,
March 2002 in “Linchuang pifuke zazhi” This study analyzed clinical manifestations of dermatomyositis in 18 patients, reporting common symptoms such as skin rash, proximal muscle weakness, and elevated serum markers, with treatment typically involving prednisolone and hydroxychloroquine.
May 2025 in “The Journal of Rheumatology” In this case report, two patients with polyautoimmunity and difficult-to-treat lupus erythematosus experienced significant symptom improvement after adding anifrolumab to their regimen, suggesting its potential as an effective add-on therapy for refractory cutaneous symptoms in autoimmune conditions characterized by elevated interferon alpha activity.
January 2002 in “대한피부과학회지” This study analyzed clinical manifestations in 18 dermatomyositis patients, noting that all exhibited skin rash and variable symptoms like itching and muscle weakness, with treatment involving prednisolone and hydroxychloroquine.